Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
XNCR
Home
/
XNCR

NASDAQ
$35.03
$35.03

Overview

Price performance
Low
$30.87
High
$35.03
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
35.03
4.39 (14.33%)
Average, 50 days
$25.81
$17.13
Open
$31.26
Previous close
$30.64
52-week high
$35.05
Nov 4, 2026 (23 hours ago)
52-week low
$10.38
May 19, 2026 (6 months ago)
237.48%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
2.60B
Volume
2 410 962
Total Return (3M)
75.85%
Total Return (1Y)
155.69%
—
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
xencor.com
About
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.

Frequently asked questions

XNCR · Xencor, Inc.

01What is Xencor, Inc. stock price today?

The current price of XNCR is $35.03 — it has increased by 14.33% since the previous close. Data as of Nov 4, 2026.

02Is Xencor, Inc. stock price growing?

XNCR is up 20.42% over the past week, up 41.02% over the past month and up 155.69% over the past year. The price is above its 200-day moving average of $17.13.

03What is XNCR stock forecast?

Analysts' average 12-month price target for XNCR is $43.86, which implies 25.21% upside from the current price. Individual estimates range from $40.00 to $46.00.

04What do analysts say about XNCR stock?

Of the 14 analysts covering Xencor, Inc., 3 rate it a strong buy, 9 rate it a buy and 2 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

05What is Xencor, Inc. market cap?

Xencor, Inc. has a market capitalization of $2.6B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

06What were Xencor, Inc. earnings last quarter?

In its most recent quarterly report, Xencor, Inc. posted a loss of $0.29 per share against an estimate of -$0.8015, beating expectations by 63.82%. Upcoming reports are listed in the earnings calendar.

07What is Xencor, Inc. revenue for the last quarter?

Xencor, Inc. reported revenue of $51.22M in its most recent quarter, which has increased by 17.46% compared with the same quarter a year earlier. Analysts had expected $18.89M.

08Does Xencor, Inc. pay dividends?

Xencor, Inc. has not paid any dividends over the past year.

09Who are Xencor, Inc. competitors?

Companies most comparable to Xencor, Inc. include Genmab A/S, Nurix Therapeutics, Inc., Celldex Therapeutics, Inc., Immunocore Holdings plc and Nektar Therapeutics.

10How volatile is XNCR stock?

In the latest trading session XNCR moved between $30.87 and $35.03, a range of 11.88% of its current price.

11Should I invest in Xencor, Inc. stock?

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Xencor, Inc. shows a strong buy rating today. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Xencor, Inc. is strong buy. Technical ratings are indicators, not investment advice.

12What are XNCR stock 52-week high and low?

Over the past 52 weeks XNCR has traded between $10.38 and $35.05. The current price is at its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.